194 related articles for article (PubMed ID: 8889343)
1. Blinding during data analysis and writing of manuscripts.
Gøtzsche PC
Control Clin Trials; 1996 Aug; 17(4):285-90; discussion 290-3. PubMed ID: 8889343
[No Abstract] [Full Text] [Related]
2. Commentary: The debate on non-inferiority trials: 'when meta-analysis alone is not helpful'.
Liberati A; D'Amico R
Int J Epidemiol; 2010 Dec; 39(6):1582-3. PubMed ID: 21113051
[No Abstract] [Full Text] [Related]
3. Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials.
Soonawala D; Middelburg RA; Egger M; Vandenbroucke JP; Dekkers OM
Int J Epidemiol; 2010 Dec; 39(6):1567-81. PubMed ID: 20837637
[TBL] [Abstract][Full Text] [Related]
4. Issues of study design and data analysis.
D'Agostino RB
Inflamm Bowel Dis; 1998 May; 4(2):109-111; discussion 111-3. PubMed ID: 9687216
[No Abstract] [Full Text] [Related]
5. The blind leading the blind: use and misuse of blinding in randomized controlled trials.
Miller LE; Stewart ME
Contemp Clin Trials; 2011 Mar; 32(2):240-3. PubMed ID: 21070890
[TBL] [Abstract][Full Text] [Related]
6. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations].
Dorhout Mees EJ
Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2228. PubMed ID: 11103264
[No Abstract] [Full Text] [Related]
7. In the dark: the reporting of blinding status in randomized controlled trials.
Montori VM; Bhandari M; Devereaux PJ; Manns BJ; Ghali WA; Guyatt GH
J Clin Epidemiol; 2002 Aug; 55(8):787-90. PubMed ID: 12384193
[TBL] [Abstract][Full Text] [Related]
8. Blinding in pharmaceutical clinical trials: An overview of points to consider.
Crisp A
Contemp Clin Trials; 2015 Jul; 43():155-63. PubMed ID: 26044462
[TBL] [Abstract][Full Text] [Related]
9. The landscape and lexicon of blinding in randomized trials.
Schulz KF; Chalmers I; Altman DG
Ann Intern Med; 2002 Feb; 136(3):254-9. PubMed ID: 11827510
[No Abstract] [Full Text] [Related]
10. Designs for efficient clinical trials.
Simon R
Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
[TBL] [Abstract][Full Text] [Related]
11. [Experimental studies].
Gili M; Lacalle JR; Velasco A
Enferm Infecc Microbiol Clin; 1990 Jan; 8(1):52-7. PubMed ID: 2095906
[No Abstract] [Full Text] [Related]
12. [Study designs for the evaluation of drug effects].
Christensen S; Christiansen CF; Sørensen HT
Ugeskr Laeger; 2009 Mar; 171(10):799-802. PubMed ID: 19265605
[TBL] [Abstract][Full Text] [Related]
13. A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials.
Mathieu E; Herbert RD; McGeechan K; Herbert JJ; Barratt AL
J Clin Epidemiol; 2014 Jun; 67(6):667-71. PubMed ID: 24767518
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical data with breached blindness.
Chow SC; Shao J
Stat Med; 2004 Apr; 23(8):1185-93. PubMed ID: 15083477
[TBL] [Abstract][Full Text] [Related]
15. How do we know what we know? The randomized controlled trial revisited.
Heaney RP
J Bone Miner Res; 1991 Feb; 6(2):103-5. PubMed ID: 2028831
[No Abstract] [Full Text] [Related]
16. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review.
Boutron I; Estellat C; Guittet L; Dechartres A; Sackett DL; Hróbjartsson A; Ravaud P
PLoS Med; 2006 Oct; 3(10):e425. PubMed ID: 17076559
[TBL] [Abstract][Full Text] [Related]
17. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
Haahr MT; Hróbjartsson A
Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
[TBL] [Abstract][Full Text] [Related]
18. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias.
Järvinen TL; Sihvonen R; Bhandari M; Sprague S; Malmivaara A; Paavola M; Schünemann HJ; Guyatt GH
J Clin Epidemiol; 2014 Jul; 67(7):769-72. PubMed ID: 24560088
[TBL] [Abstract][Full Text] [Related]
19. Blinding, pragmatism, and the PRECIS-2 tool for designing and assessing randomized trials.
Zwarenstein M; Howie A
Eur J Clin Pharmacol; 2021 Jul; 77(7):1069-1070. PubMed ID: 33394054
[No Abstract] [Full Text] [Related]
20. A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies.
Oczkowski SJ
Open Med; 2014; 8(2):e67-72. PubMed ID: 25009686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
